Journal article
A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
Abstract
Introduction This study aimed to assess the safety and tolerability of the multitargeted tyrosine kinase inhibitor, vandetanib (V), in combination with two chemotherapeutic agents, oxaliplatin (O) and docetaxel (D) in advanced gastroesophageal (GE) cancer. Methods This was a Phase I study (NCT00732745) with a standard 3 + 3 dose escalation design. The primary aim was to determine the optimal dose of the combination of vandetanib and OD …
Authors
Halmos B; Jia Y; Bokar JA; Fu P; Adelstein DJ; Juergens R; Rodal MB; Dowlati A
Journal
Investigational New Drugs, Vol. 31, No. 5, pp. 1244–1250
Publisher
Springer Nature
Publication Date
October 2013
DOI
10.1007/s10637-013-9945-8
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDose-Response Relationship, DrugGastrointestinal NeoplasmsHumansMaleMaximum Tolerated DoseMiddle AgedOrganoplatinum CompoundsOxaliplatinPiperidinesProtein Kinase InhibitorsQuinazolinesReceptors, Vascular Endothelial Growth FactorTaxoids